NEXTHERA CAPITAL LP - Q3 2018 holdings

$522 Million is the total value of NEXTHERA CAPITAL LP's 56 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 0.0% .

 Value Shares↓ Weighting
BMRN  BioMarin Pharmaceutical Inccall$29,091,000
+2.9%
300,0000.0%5.58%
+27.4%
MGTA  Magenta Therapeutics Inc$1,802,000
-11.0%
150,0000.0%0.34%
+9.9%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2018-11-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Insmed Inc13Q2 201910.0%
Global Blood Therapeutics Inc11Q2 20196.2%
Shire PLC9Q1 201813.6%
Immunomedics Inc9Q2 20197.8%
Allergan PLC8Q2 20197.6%
FibroGen Inc8Q3 20183.0%
Abeona Therapeutics Inc8Q3 20182.1%
Pfizer Inc7Q2 201719.1%
Seattle Genetics Inc7Q2 20185.7%
Mylan NV7Q2 20196.5%

View NEXTHERA CAPITAL LP's complete holdings history.

Latest significant ownerships (13-D/G)
NEXTHERA CAPITAL LP Q3 2018 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
CATALYST BIOSCIENCES, INC.February 14, 2019376,0103.1%
CHIASMA, INCFebruary 14, 20191,066,4394.4%
ONCOSEC MEDICAL IncSold outFebruary 14, 201900.0%
Zosano Pharma CorpApril 05, 2018700,0005.9%
VistaGen Therapeutics, Inc.May 24, 2016138,1321.8%

View NEXTHERA CAPITAL LP's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2019-08-14
13F-HR2019-05-15
13F-HR2019-02-14
SC 13G/A2019-02-14
SC 13G/A2019-02-14
SC 13G/A2019-02-14
SC 13G2018-11-26
13F-HR2018-11-14
13F-HR2018-08-14
SC 13G2018-06-11

View NEXTHERA CAPITAL LP's complete filings history.

Compare quarters

Export NEXTHERA CAPITAL LP's holdings